Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Exemestane + Saruparib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Exemestane | Aromasin | Aromatase Inhibitor 3 | Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary). | |
| Saruparib | AZD 5305|AZD-5305|AZD5305 | PARP-1 Inhibitor 13 | Saruparib (AZD5305) inhibits PARP1, potentially leading to tumor growth inhibition (PMID: 35929986). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06380751 | Phase III | Ribociclib Anastrozole Letrozole Anastrozole + Saruparib Fulvestrant + Saruparib Letrozole + Saruparib Exemestane Abemaciclib Exemestane + Saruparib Fulvestrant Camizestrant + Saruparib Camizestrant + Ribociclib Camizestrant + Palbociclib Abemaciclib + Camizestrant Palbociclib | Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 12 |